Although the use of EGFR‐TKIs has shown benefits for patients with advanced NSCLC and EGFR mutations, it is inevitable that tumor cells will develop drug resistance, thus leading to disease progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.